Investment Risk Analysis: Safe Obstetric Systems Limited

1. Risk Rating: MEDIUM

Justification: While the company exhibits a strong net asset position (£2.7M) and growing revenue, significant concerns arise from the substantial IP transfer to its US parent affiliate in 2021, the collapse in operating profit from £1,806k to £23k post-transfer, and volatile cash movements. The company's strategic autonomy appears compromised by its group structure, and the sustainability of future earnings is uncertain following the disposal of key intangible assets.

2. Key Concerns

Concern 1: IP Transfer and Profitability Collapse

The 2021 disposal of intangible property assets to CooperSurgical Inc (a subsidiary of The Cooper Companies Inc) fundamentally altered the company's earnings profile. Operating profit fell from £1,806k (2021) to just £23k (2022), and profit before tax dropped from £36,685k to £59k. The 2021 figures were clearly inflated by this one-time transaction, and the dramatic decline suggests the company may have ceded its primary revenue-generating IP to the parent entity. The question remains: what sustainable competitive advantage and revenue stream does the company retain?

Concern 2: Extreme Cash Volatility

Cash positions have exhibited concerning volatility: £1,613,597 (2020), dropping to £27,453 (2021), then partially recovering to £227,793 (2022). The near-98% decline in cash between 2020 and 2021 is alarming and warrants investigation into whether this reflects intercompany cash extraction, dividend payments upstream, or operational cash burn. A cash-to-turnover ratio of approximately 11.6% (2022) provides limited liquidity buffer for a medical device company facing regulatory and product development costs.

Concern 3: Group Dependency and Related-Party Risk

The company is described as "an affiliated company of CooperSurgical" with directors who are predominantly American corporate executives (Calcagno, Blair, Andrews, Ricupati). This structure creates significant related-party risk. Intercompany transactions, transfer pricing arrangements, and the direction of strategic decisions may prioritise group interests over those of minority shareholders. The PSC register shows the Varma family (Dr Rajiv Varma, Mrs Balpreet Varma, and Mr Nishant Varma) holding 25-50% ownership each alongside Mr Innes Taylor's significant influence—this bifurcation between US corporate directors and UK-based PSCs creates potential governance tension.

3. Positive Indicators

Strong Balance Sheet

Net assets have grown consistently from -£76,370 (2013) to £2,716,227 (2022), demonstrating a remarkable long-term turnaround. Total liabilities of £446,312 against total assets of £3,162,043 yield a healthy debt-to-asset ratio of approximately 14%.

Revenue Growth and Market Position

Turnover increased 11% year-on-year to £1.97M, with the company reporting that revenue growth "outperformed the market." The Fetal Pillow® product appears to have established market traction, and UK market share is reportedly growing.

Group Backing

Affiliation with CooperSurgical and The Cooper Companies Inc provides access to global distribution networks, research resources, and implicit financial support. The going concern assessment references consolidated cash flow forecasts, suggesting group-level financial planning.

Regulatory Compliance

Accounts and confirmation statements are filed on time. The company files full (not abbreviated) accounts, demonstrating transparency. No disqualification orders are noted against directors.

4. Due Diligence Notes

Critical Items to Investigate:

1. IP Transfer Agreement Terms: Obtain and review the 2021 IP Transfer agreement with CooperSurgical Inc. Determine whether the company retains any licensing rights, royalty income, or whether it has effectively become a contract manufacturer/distributor for its own former IP.

2. Intercompany Balances and Transactions: The financial statements reference consolidated cash flow forecasts and a subsidiary in Australia. Full disclosure of intercompany receivables, payables, and management charges is essential. Determine whether cash was extracted via intercompany settlements in 2021.

3. Asset Composition: The total assets of £3.16M require decomposition. How much comprises intangible assets (patents, trademarks) versus tangible assets versus trade debtors? Given the IP transfer, the nature and recoverability of remaining assets is critical.

4. Profit Sustainability: With operating profit of only £23k on nearly £2M revenue (approximately 1.2% margin), clarify the cost structure and whether margins can support ongoing operations without group subsidies.

5. PSC vs. Director Dynamics: Investigate the relationship between the Varma family PSCs (who appear to be the original founders/inventors) and the US-based CooperSurgical-appointed directors. Understand whether minority shareholder interests are adequately protected.

6. Cash Flow Patterns: Request detailed cash flow statements for 2020-2022 to understand the drivers behind the extreme cash movements, particularly the £1.59M outflow between 2020 and 2021.

7. Regulatory Environment: As a medical device manufacturer (SIC 32500), understand the company's compliance with UK MDR 2002 and any implications from the UK's post-Brexit regulatory framework for medical devices.